Anthony Faucini, the country’s best communicable disease specialist, said the widespread phenomenon in the final stages of the pandemic was the rise of COVID-19 after a course of anti-Paxlovid drugs.
In an interview at the Global Health Forum on Tuesday, Fauki said his infection had passed until his current recovery, which he said was much worse than the first round of the disease. Fauki, director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health and chief medical adviser to the president, is 81 years old and has been fully vaccinated against COVID-19 and has been vaccinated twice.
He first tested positive for the express antigen on June 15 and experienced “very minimal symptoms.” However, his symptoms worsened and he began a five-day course in Paxlovid. “And I felt so good,” Fauki said, adding that he just had a runny nose and fatigue. After he completed the five-day course, he had negative antigen tests for three days in a row. But then “on the fourth day – to be sure – I tested myself again, came back positive … and then the next day or so I started to feel really bad, worse than the first time I went around.”
Fauki then returned to Paxlovid for another five-day course. “Now I am in the fourth day of Pakslovid’s second five-day course,” he said on Tuesday. “And, fortunately, I feel good, so I’m not completely free of symptoms, but I’m definitely not seriously ill.”
Conflict Treatment Council
Fauki’s second course of treatment contradicts the position of the US Food and Drug Administration and the Centers for Disease Control and Prevention. At a health consultation on May 24, the CDC wrote: “There is currently no evidence that additional treatment for COVID-19 is necessary. According to current data, patient monitoring is the most appropriate management. Patients with recurrent symptoms after completing a course of paxlovid treatment.
Similarly, the FDA stated in May that “there is currently no benefit to a long course of treatment … or there is no benefit to repeating a course of Paxlovid treatment in patients with recurrent COVID-19 symptoms after the end of treatment”.
However, Albert Burla, CEO of Pfizer, the company that made Paxlovid, said a second course of Paxlovid could be used to treat relapsed cases.
how and why
Apart from questions about how to treat Rebun, it is not known how common they are or why they occur. The CDC notes that recurrent symptoms of COVID-19 are not limited to people taking Paxlovid. “A brief recurrence of symptoms may be part of the natural history of SARS-CoV-2 (the virus that causes COVID-19) infection, regardless of treatment with Paxlovid and regardless of vaccination status,” the agency wrote. health warning.
This corresponds to Pfizer’s initial clinical data on Paxlovid, which ranged from about 1 percent to 2 percent. both of them The treatment and placebo groups were raised in trials. However, as Paxlovid is now more widely accepted, anecdotal reports of post-Paxlovid rebounds have surfaced on social media.
Experts are still trying to figure out why there was a backlash. Last week, researchers at Fauci’s NIAID confirmed the findings of a small study, which was partly due to a resurgence of immune responses as the body quickly clears dead human cells and viral debris after an infection has subsided. The study found no evidence for possible explanations for the resurgence, such as whether SARS-CoV-2 is mutated to block Paxlovid or whether the human immune system is unable to protect against the virus. In addition, limited data published by the CDC suggests that rehabilitated individuals do not suffer more severely from COVID-19 requiring hospitalization or emergency care.